Loading...
RXK3 logo

SELLAS Life Sciences Group, Inc.DB:RXK3 Stock Report

Market Cap €776.3m
Share Price
€4.02
€8.15
50.7% undervalued intrinsic discount
1Y166.6%
7D6.9%
Portfolio Value
​
View

SELLAS Life Sciences Group, Inc.

DB:RXK3 Stock Report

Market Cap: €776.3m

SELLAS Life Sciences Group (RXK3) Stock Overview

A late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. More details

RXK3 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


RXK3 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives
UNCY logo
UNCYFeatured

Looking to be second time lucky with a game-changing new product

Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
View narrative
Community Contributor
US$21.53FV • 64.4% undervalued intrinsic discount
5419.8%Revenue growth p.a.
6.2k
18
0
128
3mo ago

SELLAS Life Sciences Group, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for SELLAS Life Sciences Group
Historical stock prices
Current Share PriceUS$4.02
52 Week HighUS$5.36
52 Week LowUS$1.20
Beta2.23
1 Month Change12.61%
3 Month Change19.29%
1 Year Change166.58%
3 Year Change183.50%
5 Year Change-37.33%
Change since IPO-98.56%

Recent News & Updates

Recent updates

Shareholder Returns

RXK3DE BiotechsDE Market
7D6.9%3.6%0.06%
1Y166.6%-11.2%1.0%

Return vs Industry: RXK3 exceeded the German Biotechs industry which returned -11.2% over the past year.

Return vs Market: RXK3 exceeded the German Market which returned 1% over the past year.

Price Volatility

Is RXK3's price volatile compared to industry and market?
RXK3 volatility
RXK3 Average Weekly Movement14.0%
Biotechs Industry Average Movement8.7%
Market Average Movement6.0%
10% most volatile stocks in DE Market12.3%
10% least volatile stocks in DE Market2.6%

Stable Share Price: RXK3's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: RXK3's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
n/a13Angelos Stergiousellaslifesciences.com

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK’s WT1 peptide vaccine technology.

SELLAS Life Sciences Group, Inc. Fundamentals Summary

How do SELLAS Life Sciences Group's earnings and revenue compare to its market cap?
RXK3 fundamental statistics
Market cap€776.29m
Earnings (TTM)-€22.92m
Revenue (TTM)n/a
0.0x
P/S Ratio
-33.9x
P/E Ratio

Is RXK3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RXK3 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$26.86m
Earnings-US$26.86m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.15
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did RXK3 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/03 18:58
End of Day Share Price 2026/04/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SELLAS Life Sciences Group, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Aydin HuseynovLadenburg Thalmann & Company
Jason McCarthyMaxim Group